Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VENTRITEX FIRST QUARTER 1995 REVENUES UP 62.7% TO $29 MIL., BUT 10% SALES DROP FROM FOURTH QUARTER 1994 REFLECTS MDs' CADENCE/LEAD REIMBURSEMENT ANXIETY

This article was originally published in The Gray Sheet

Executive Summary

Ventritex' first quarter 1995 revenues increased 62.7% over the prior-year period to $29 mil., marching to the beat of growing sales of the firm's Cadence implantable defibrillator. Quarterly earnings were $2.5 mil., turning around the company's $1.8 mil. loss during first quarter 1994.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel